817210-68-7

Upstream product

• 178034-11-2 (3R,5S)-(+)-3-acetoxy-5-(trimethylacetyloxy)cyclopent-1-ene 
• 178034-12-3 (1S,4R)-4-hydroxycyclopent-2-enyl 2,2,2-trimethylacetate 
• 60410-16-4 (1R,4S)-4-hydroxy-2-cyclopentene-1-yl acetate 
• 865302-28-9 (3R,5S)-(+)-3-[(1,1-dimethylethyl)diphenylsilyloxy]-5-(trimethylacetyloxy)cyclopent-1-ene 

Downstream Products

• 122552-67-4 (4R)-(+)-2-bromo-4-[(1,1-dimethylethyl)diphenylsilyloxy]cyclopent-2-en-1-one 
• 865302-38-1 C₆₀H₉₆NO₁₁PSi 
• 865302-32-5 (4R,5R)-(+)-2-[(1,1-dimethylethyl)dimethylsilyloxy]-4-[(1,1-dimethylethyl)diphenylsilyloxy]-5-(2Z-octenyl)-α-[(1R,2R)-1,2-epoxy-6-(4-methoxyphenylmethoxy)hexyl]cyclopent-2-enemethanol 
• 865302-33-6 (3R,4R)-(+)-2E-2-[(2R,3R)-2,3-epoxy-7-(4-methoxyphenylmethoxy)hept-1-enyl]-4-[(1,1-dimethylethyl)diphenylsilyloxy]-3-(2Z-octenyl)-cyclopentanone 
• 865302-36-9 (2R,3R)-3-Z-[(4R,5R)-5-(2Z-octenyl)-2-oxo-4-[(1,1-dimethylethyl)diphenylsilyloxy]cyclopentylidenemethyl]oxirane-2-butanoic acid 
• 865302-34-7 (3R,4R)-(+)-2E-2-[(2R,3R)-2,3-epoxy-7-hydroxyhept-1-enyl]-4-[(1,1-dimethylethyl)diphenylsilyloxy]-3-(2Z-octenyl)-cyclopentanone 
• 865302-35-8 (3R,4R)-(+)-2E-2-[(2R,3R)-2,3-epoxy-7-oxohept-1-enyl]-4-[(1,1-dimethylethyl)diphenylsilyloxy]-3-(2Z-octenyl)-cyclopentanone 
• 865302-31-4 (3S,4R)-(+)-2-bromo-1-[(1,1-dimethylethyl)dimethylsilyloxy]-4-[(1,1-dimethylethyl)diphenylsilyloxy]-3-(2Z-octenyl)cyclopent-1-ene 
• 865302-29-0 (3S,4R)-(+)-2-bromo-3-ethenyl-1-[(1,1-dimethylethyl)dimethylsilyloxy]-4-[(1,1-dimethylethyl)diphenylsilyloxy]cyclopent-1-ene 
• 865302-30-3 (1S,5R)-2-bromo-3-[(1,1-dimethylethyl)dimethylsilyloxy]-5-[(1,1-dimethylethyl)diphenylsilyloxy]cyclopent-2-ene-acetaldehyde 
• 107657-42-1 (4R)-(+)-4-[(1,1-dimethylethyl)diphenylsilyloxy]cyclopent-2-en-1-one 

Relevant academic research and scientific papers

Total synthesis of the epoxy isoprostane phospholipids PEIPC and PECPC

(Chemical Equation Presented) A total synthesis of the naturally occurring hydroxy ketone PEIPC 1, a compound that plays a role in endothelial activation in atherosclerosis, has been completed via a triply convergent preparation of a protected EI derivative 13 from 3,5-diacetoxycyclopentene 7, pentane-1,5-diol, and vinyllithium, using Sharpless epoxidation and enzymatic resolution as key steps. Final coupling with lyso-PC 16 and silyl group deprotection gave PECPC 2 and PEIPC 1, which showed the same activity as natural PECPC and PEIPC.